BCDA BioCardia, Inc. Insider Trading

Director Simon H Stertzer purchases 109,200 shares (191.1% increase) at BioCardia for $103,584 across two transactions at $0.92 and $1.00.

Simon H Stertzer, a Director at BioCardia, executed 2 purchases totaling 109,200 shares for $103,584.00, raising his holdings from 57,138 to 166,338 shares—a 191.1% increase. The purchases occurred at $0.92 (70,200 shares on 2026-06-22) and $1.00 (39,000 shares on 2026-06-23), with a blended average price of $0.95, slightly below the current price of $1.06 but -56.7% from the 52-week high of $2.45. His prior transaction history at this ticker shows mixed near-term timing: 2 of 5 prior buys at BCDA yielded positive 90-day returns (trades on 2025-09-19 and 2025-04-23 gained +16.0% and +20.5% respectively at the 90-day mark), while others underperformed, including the most recent buy on 2025-06-30 which declined -31.6% over 90 days. BioCardia's fundamentals are materially stressed—the company reported $0.00 revenue (latest quarter), a net loss of $-2,259,000.00, and -100.0% annual revenue growth, with a market capitalization of only $12,057,207.44. The substantial share accumulation by a director into a loss-making, revenue-depleted micro-cap warrants investor scrutiny of both the director's conviction on the turnaround thesis and the company's capital adequacy and operational path forward.

BioCardia CEO Peter Altman buys 5,000 shares at depressed valuation amid company's sharp stock decline and ongoing losses.

Peter Altman, BioCardia's President and CEO, purchased 5,000 shares at a time when the stock is trading sharply below its highs following a steep recent decline. This is a meaningful signal of insider conviction—the company's CEO is putting his own capital at risk despite the stock's weakness and the company's fundamental challenges of unprofitable operations and contracting revenue. The trade is particularly noteworthy because Altman is buying into fundamental headwinds (the company remains deeply unprofitable with declining revenue trends), suggesting he believes the current depressed valuation offers a compelling entry point. For a CEO to accumulate shares in a loss-making biotech company during a downturn signals either that he sees a near-term catalyst or views the current price as a substantial discount to intrinsic value—both worth investigating further.

CEO Altman bought 1,000 shares at $1.23 (2 purchases, $1,230) as stock trades -61.8% from 52-week high

Peter Altman, President and CEO, made 2 separate purchases totaling 1,000 shares for $1,230.00 at a blended average price of $1.23 on April 20–21, 2026. The current stock price of $1.20 is now -61.8% from the 52-week high of $3.14, and the company is reporting zero revenue in the latest quarter with a net loss of $-1,483,000 and -100.0% annual revenue decline. His prior trades at BCDA show a 0% 90-day win rate (0 of 2 prior measurable buys produced positive 90-day returns), and his cross-ticker track record similarly shows a 17.65% 90-day win rate with an average 90-day return of -13.1%. The purchase occurs as the stock is trading near its 52-week lows and fundamentals remain severely distressed, but Altman's historical timing on both this ticker and across all his open-market buys suggests limited predictive value for near-term recovery.

BioCardia CEO Altman buys 900 shares in 2 transactions ($1.23 avg) amid -62.4% 52-week decline; same-ticker pattern shows 0 of 5 prior buys well-timed at 90d.

Peter Altman, President and CEO of BioCardia, purchased 900 shares across 2 separate transactions on 2026-03-24 and 2026-03-25 at a blended average price of $1.23, adding modestly to his 274.8K-share position. The company's fundamentals are severely stressed: latest-quarter revenue is $0.00, annual revenue has declined -100.0% year-over-year, and net income was $-1.5M with a market cap of only $12.9M. The stock is currently trading at $1.18, down -62.4% from its 52-week high of $3.14 and down -7.1% over the past 90 days. Against this backdrop, Altman's prior buy activity at BioCardia tells a cautionary story: of 5 prior recorded trades at this ticker, 0 of 2 measurable outcomes were well-timed at the 90-day mark, with his most recent prior buys (2026-01-20 and 2026-01-21) showing 90-day returns of -12.1% and -15.7% respectively. The current purchase arrives in the context of these repeated underperforming buy decisions at the same company.

CEO Peter Altman bought 5,000 BCDA shares at $1.13; 5th open-market purchase in 3 months as stock trades -65.3% from 52-week high.

Peter Altman, President and CEO, purchased 5,000 shares at $1.13 on 2026-02-04, his fifth discretionary open-market buy at BioCardia in the past three months. The stock has declined -65.3% from its 52-week high of $3.14 and currently trades at $1.09, below the transaction price. The company is unprofitable with net income of $-1,483,000 and annual revenue declined -87.8%, yet Altman continues to accumulate shares, increasing his holdings to 273.9K shares. His prior same-ticker buys show mixed results: the oldest measurable buy from 2025-09-19 returned +2.4% over 90 days, while recent purchases from late January 2026 remain outcome-indeterminate. The frequency of purchases during a steep decline and unprofitable operating environment warrants scrutiny of underlying circumstances.

BCDA CEO Peter Altman buys 900 shares at $1.33 avg (2 txns), now underwater on current $1.28 price; stock down 59.2% from 52-week high.

Peter Altman, President and CEO, purchased 900 shares across 2 transactions totaling $1,194.00 at a blended average price of $1.33 per share on 2026-01-20 and 2026-01-21. The current price of $1.28 is already below his transaction average and represents a 59.2% decline from the 52-week high of $3.14. At BioCardia specifically, Altman's prior 5 trades show a mixed record: only 1 of 3 prior buys measurable at the 90-day mark were well-timed (positive returns), while two earlier purchases delivered 90-day losses of -30.0% and -27.3%. The company's fundamentals are distressed—latest quarterly revenue is $0.00 with a net loss of $-1.5M, annual revenue growth declined 87.8%, and the market cap sits at $13.6M. His post-transaction holdings increased only 0.3% to 268.9K shares, a modest increase relative to the stock's volatility and the company's deteriorating financial position.

CEO Altman purchases 1,100 shares across 2 days at $1.31 blended average; stock down 59.6% from 52-week high

Peter Altman, President and CEO of BioCardia (BCDA), executed 2 separate purchases totaling 1,100 shares for $1,444.00 on December 16–17, 2025, at a blended average price of $1.31, raising his holdings to 268.0K shares. The company is unprofitable (net income -$1.5M in latest full year) with zero quarterly revenue and annual revenue growth of -87.8%, while the stock trades 59.6% below its 52-week high of $3.14. Altman's same-ticker history shows 5 prior buys at BCDA, with a timing pattern of 0 of 4 measurable outcomes well-timed at the 90-day mark (all four showed negative 90-day returns averaging -27.4%). His cross-ticker buy track record shows a 31.58% 90-day win rate and average 90-day return of -9.1%, suggesting a pattern of purchases that have not recovered materially in subsequent quarters.

Director Blank buys 288.0K shares at $1.25 (+83.2% to holdings); stock down -37.3% in 90 days amid $-2.0M net loss, cluster buy pattern

Blank Andrew Scott (Director) purchased 288,000 shares at $1.25 on 2025-09-19, increasing holdings by 83.2% to 634,023 shares. This transaction occurs amid deteriorating company fundamentals: latest quarter revenue was $0.00, net income was $-2,049,000.00, and annual revenue growth shows a decline of -87.8%. The stock has fallen -37.3% over the past 90 days and is currently trading -55.1% below its 52-week high of $3.14. Notably, 2 other insiders also bought within the past 14 days, indicating a coordinated cluster buy pattern, while Blank's prior two purchases at BCDA (on 2025-06-30 and 2025-04-23) both generated positive 30-day returns and the earlier trade achieved a 90-day gain of +20.5%. The timing and magnitude of this purchase against both the steep price decline and severe operational headwinds warrant careful assessment of the underlying strategic intent.

Director STERTZER SIMON H bought 398,400 BCDA shares at $1.25; stock down -26.2% in 30 days, -37.3% in 90 days; company unprofitable with -87.8% revenue decline

Director Stertzer purchased 398,400 shares worth $498,000.00 on 2025-09-19, more than tripling his position from 192,654 shares to 591,054 shares. This acquisition occurs within a cluster of 2 other insider purchases in the past 14 days. However, the timing relative to recent price action raises concerns: BCDA shares have declined -26.2% over the prior 30 days and -37.3% over the prior 90 days from the purchase date, and the stock currently trades at $1.41, down -55.1% from its 52-week high of $3.14. Compounding this context, the company reported zero revenue in the latest quarter, a net loss of $-2,049,000.00, and annual revenue contraction of -87.8%, with negative full-year net income. Stertzer's prior trades at BCDA show mixed timing: 1 of 4 prior measurable buys achieved a positive 90-day return (the April 2025 purchase), while 3 of 4 resulted in declines at the 90-day mark. The cluster pattern and large purchase size warrant monitoring, but the company's deteriorating fundamentals and the director's uneven execution on prior BCDA trades indicate execution risk.

CEO Altman buys 48.0K BCDA shares at $1.25; stock down 55.1% from 52-week high; 2 other insiders buying in 14-day cluster.

Peter Altman, President and CEO, purchased 48,000 shares at $1.25 on 2025-09-19, increasing his holdings by 28.4%. The company is in severe distress: revenue was $0.00 in the latest quarter, net income was $-2,049,000.00, and annual revenue growth contracted by -87.8%. The stock has declined 55.1% from its 52-week high of $3.14 and dropped 26.2% over the past 30 days. Across his prior trades at BCDA, Altman's timing has been inconsistent; his most recent buy on 2025-08-22 saw a 30-day loss of -36.6%, suggesting continued downward pressure. The filing reveals a cluster pattern: 2 other insiders also bought within the past 14 days, which may reflect an attempt to stabilize investor confidence, though the fundamental deterioration (zero revenue, expanding losses, severe revenue contraction year-over-year) raises questions about sustainability.